AUPP765398A0 - Treatment of papillomavirus infections - Google Patents

Treatment of papillomavirus infections

Info

Publication number
AUPP765398A0
AUPP765398A0 AUPP7653A AUPP765398A AUPP765398A0 AU PP765398 A0 AUPP765398 A0 AU PP765398A0 AU PP7653 A AUPP7653 A AU PP7653A AU PP765398 A AUPP765398 A AU PP765398A AU PP765398 A0 AUPP765398 A0 AU PP765398A0
Authority
AU
Australia
Prior art keywords
treatment
infection
vlps
papillomavirus infections
papillomavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPP7653A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Original Assignee
University of Queensland UQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Priority to AUPP7653A priority Critical patent/AUPP765398A0/en
Publication of AUPP765398A0 publication Critical patent/AUPP765398A0/en
Priority to EP99966765A priority patent/EP1144005B1/en
Priority to PCT/AU1999/001108 priority patent/WO2000035478A1/en
Priority to ZA9907638A priority patent/ZA997638B/xx
Priority to KR1020017007244A priority patent/KR100617485B1/ko
Priority to AT99966765T priority patent/ATE344053T1/de
Priority to AU22674/00A priority patent/AU762114B2/en
Priority to US09/868,009 priority patent/US6867033B1/en
Priority to DK99966765T priority patent/DK1144005T3/da
Priority to CA2353866A priority patent/CA2353866C/en
Priority to DE69933891T priority patent/DE69933891T2/de
Priority to JP2000587797A priority patent/JP5274737B2/ja
Priority to NZ512850A priority patent/NZ512850A/xx
Priority to US11/079,525 priority patent/US7172870B2/en
Priority to JP2010261979A priority patent/JP2011037902A/ja
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AUPP7653A 1998-12-11 1998-12-11 Treatment of papillomavirus infections Abandoned AUPP765398A0 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
AUPP7653A AUPP765398A0 (en) 1998-12-11 1998-12-11 Treatment of papillomavirus infections
NZ512850A NZ512850A (en) 1998-12-11 1999-12-13 Treatment of papillomavirus infections
AU22674/00A AU762114B2 (en) 1998-12-11 1999-12-13 Treatment of papillomavirus infections
DK99966765T DK1144005T3 (da) 1998-12-11 1999-12-13 Behandling af papillomavirusinfektioner
ZA9907638A ZA997638B (en) 1998-12-11 1999-12-13 Treatment of papillomavirus infections.
KR1020017007244A KR100617485B1 (ko) 1998-12-11 1999-12-13 파필로마바이러스 감염의 치료
AT99966765T ATE344053T1 (de) 1998-12-11 1999-12-13 Behandlung von papillomavirus-infektionen
EP99966765A EP1144005B1 (en) 1998-12-11 1999-12-13 Treatment of papillomavirus infections
US09/868,009 US6867033B1 (en) 1998-12-11 1999-12-13 Treatment of papillomavirus infections
PCT/AU1999/001108 WO2000035478A1 (en) 1998-12-11 1999-12-13 Treatment of papillomavirus infections
CA2353866A CA2353866C (en) 1998-12-11 1999-12-13 Treatment of papillomavirus infections
DE69933891T DE69933891T2 (de) 1998-12-11 1999-12-13 Behandlung von papillomavirus-infektionen
JP2000587797A JP5274737B2 (ja) 1998-12-11 1999-12-13 パピローマウイルス感染の治療方法
US11/079,525 US7172870B2 (en) 1998-12-11 2005-03-15 Treatment of papillomavirus infections
JP2010261979A JP2011037902A (ja) 1998-12-11 2010-11-25 パピローマウイルス感染の治療方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPP7653A AUPP765398A0 (en) 1998-12-11 1998-12-11 Treatment of papillomavirus infections

Publications (1)

Publication Number Publication Date
AUPP765398A0 true AUPP765398A0 (en) 1999-01-14

Family

ID=3811858

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPP7653A Abandoned AUPP765398A0 (en) 1998-12-11 1998-12-11 Treatment of papillomavirus infections

Country Status (12)

Country Link
US (2) US6867033B1 (https=)
EP (1) EP1144005B1 (https=)
JP (2) JP5274737B2 (https=)
KR (1) KR100617485B1 (https=)
AT (1) ATE344053T1 (https=)
AU (1) AUPP765398A0 (https=)
CA (1) CA2353866C (https=)
DE (1) DE69933891T2 (https=)
DK (1) DK1144005T3 (https=)
NZ (1) NZ512850A (https=)
WO (1) WO2000035478A1 (https=)
ZA (1) ZA997638B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100629028B1 (ko) * 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
AUPP765398A0 (en) 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
FR2802426B1 (fr) * 1999-12-15 2004-04-02 Neovacs Utilisation de proteines immunogenes immunosuppressives et/ou angiogeniques rendues inactives, pour la production d'iga secretoires
AUPR446801A0 (en) 2001-04-18 2001-05-17 University Of Queensland, The Novel compositions and uses therefor
EP1422526A1 (en) * 2002-10-28 2004-05-26 MTM Laboratories AG Method for improved diagnosis of dysplasias
EP1877087B1 (en) 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
JP6920694B2 (ja) 2015-12-04 2021-08-18 シアメン ユニバーシティＸｉａｍｅｎ Ｕｎｉｖｅｒｓｉｔｙ ヒトパピローマウイルスタイプ１１のｌ１タンパク質の突然変異
US11389525B2 (en) * 2017-10-27 2022-07-19 Statens Serum Institut Polygene influenza vaccine
WO2023196884A1 (en) 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Detection assay for human papillomavirus (hpv) type 16 (hpv-16)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2194839T3 (es) 1991-07-19 2003-12-01 Univ Queensland Vacuna de papilomavirus.
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
ATE328068T1 (de) * 1994-05-16 2006-06-15 Merck & Co Inc Papillomavirus vakzine
EP0793752B1 (en) * 1994-09-06 2003-07-09 Scan-Web I/S A method and a system for manufacturing broad airlaid paper webs containing an absorbing powder
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US5821087A (en) 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
WO1998010790A1 (en) * 1996-09-11 1998-03-19 Merck & Co., Inc. Papillomavirus vaccine formulation
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ATE341339T1 (de) * 1996-12-20 2006-10-15 Merck & Co Inc Zusammensetzungen von rekombinanten papillomavirus vakzinen
PT973546E (pt) * 1997-04-08 2004-06-30 Merck & Co Inc Formulacoes estabilizadas de virus de papiloma humano
DE19735118C1 (de) * 1997-08-13 1998-08-13 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
US6228368B1 (en) 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
AUPP765398A0 (en) 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties

Also Published As

Publication number Publication date
ZA997638B (en) 2000-07-06
US6867033B1 (en) 2005-03-15
WO2000035478A1 (en) 2000-06-22
CA2353866C (en) 2013-11-19
US7172870B2 (en) 2007-02-06
DK1144005T3 (da) 2007-03-05
EP1144005A4 (en) 2005-02-09
NZ512850A (en) 2004-01-30
KR100617485B1 (ko) 2006-09-01
KR20010103711A (ko) 2001-11-23
EP1144005A1 (en) 2001-10-17
DE69933891T2 (de) 2007-06-21
JP2011037902A (ja) 2011-02-24
CA2353866A1 (en) 2000-06-22
US20050244433A1 (en) 2005-11-03
JP2002532434A (ja) 2002-10-02
JP5274737B2 (ja) 2013-08-28
EP1144005B1 (en) 2006-11-02
DE69933891D1 (de) 2006-12-14
ATE344053T1 (de) 2006-11-15

Similar Documents

Publication Publication Date Title
DE60119734D1 (de) Hpv-e7 zur behandlung von menschlichem papillomavirus
AU2002360592A1 (en) Inhibitors of hepatitis c virus
AU3998400A (en) Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor
WO2000074689A8 (en) Unfermented gel fraction from psyllium seed husks
AU3475097A (en) Substituted cyclopentane compounds useful as neuraminidase inhibitors
AU2002368274A1 (en) Methods of treating infection by drug resistant bacteria
LU91314I2 (fr) "Combinaison de particules viroides de papillomavirus humain de type 6, 11, 16 et 18 (GARDASIL -GilGARD )"
AU2002365240A1 (en) Method and system for early detection of infectious diseases or symptoms of bioterrorism attacks
AUPP765398A0 (en) Treatment of papillomavirus infections
AU2001234521A1 (en) Methods of using a beverage composition
AU1271799A (en) Methods for preventing and treating bacterial infections using cellulose ace tatephthalate or hydroxypropyl methylcellulose phthalate excipients
AU4033600A (en) Method for detection of auditory evoked potentials
AU4149699A (en) Use of inactivated immunosuppressive and/or angiogenic immunogenic proteins, preparation method and pharmaceutical or vaccine uses
AU4602897A (en) Method for treatment of immunodeficiency virus infection
AU2420001A (en) Methods and compositions for the treatment of pain
FR2725990B1 (fr) Derives hydrosolubles d'epipodophyllotoxine, leur procede de preparation, leur utilisation a titre de medicament, et leur utilisation destinee aux traitements anticancereux
AU2001294647A1 (en) Method or treatment of tumors using transforming growth factor-alpha
AU8892198A (en) Bio-pharmaceutical preparation containing a live culture of bacillus and method for treating viral and bacterial infections as well as immuno-deficiency conditions
AU2124100A (en) Novel process for the removal of a silyloxy protecting group from 4-silyloxy-tetrahydro-pyran-2-ones
SU1503804A1 (ru) Способ мирингопластики
AU4800500A (en) Method for treatment of lyme disease
AU4952393A (en) New hiv-1 isolates of a subtype and its differential diagnosis, vaccine against hiv-1 infection of this subtype and process for preparing and using the hiv-1 isolate
AU6295600A (en) Method for preparing 2-(2-arylmorpholin-2-yl)ethanol derivatives and intermediates
AU2120502A (en) Orally ingestible preparation of mistletoe lectins and method
AU2382601A (en) Novel method of treatment